Test All mRNA HPV assays pooled Aptima NucliSens EasyQ HPV OncoTect PreTect HPV Proofer Quantivirus CIN1- vs. CIN2+ Sensitivity 83.3 (82.9-84.6) 92.8 (91.9-93.7) 75.9 (72.7-78.9) 72.4 (67.5-76.9) 73.2 (71.5-74.9) 86.6 (82.4-90.1) Specificity 65.2 (64.5-65.8) 60.5 (59.8-61.3) 61.5 (58.5-64.5) 79.5 (77.4-81.5) 79.4 (78.3-80.5) 38.9 (35.1-42.8) DOR 10.54 (8.35-13.29) 12.53 (8.97-17.52) 5.48 (3.37-8.89) 13.83 (6.40-29.86) 13.21 (8.55-20.41) 4.71 (2.59-8.57) AUC 0.84 (0.81-0.87) 0.88 (0.82-0.95) 0.76 (0.69-0.82) 0.87 (0.82-0.92) 0.84 (0.79-0.89) 0.80 (0.66-0.95) TP 5,840 3,220 578 267 1,992 278 FP 7,910 6,177 392 319 1,125 390 FN 1,131 248 184 102 728 43 TN 14,793 9,470 627 1,238 4,337 248 N total 29,674 19,115 1,781 1,926 8,182 959 CIN1- vs. CIN3+ Sensitivity 86.1 (84.8-87.3) 95.6 (94.5-96.5) 83.5 (73.9-90.7) 85.2 (77.4-91.1) 67.6 (64.3-70.7) 85.1 (78.8-90.1) Specificity 65.5 (64.8-66.2) 61.9 (61.1-62.7) 64.1 (55.3-72.3) 78.6 (77.6-80.6) 83.9 (82.2-85.5) 41.5 (36.9-46.2) DOR 18.93 (12.44-28.82) 21.45 (12.40-37.11) 9.67 (0.931-100.54) 23.33 (8.07-67.49) 19.57 (4.36-87.85) 7.28 (4.11-12.88) AUC 0.88 (0.84-0.92) 0.91 (0.84-0.99) 0.78 (0.56-0.99) 0.84 (0.78-0.89) 0.71 (0.67-0.76) 0.79 (0.68-0.89) TP 2,494 15 71 98 579 143 FP 6,238 174 98 351 311 261 FN 403 0 14 17 278 25 TN 11,854 1,799 297 1,292 1,621 185 N total 20,989 1,988 480 1,758 2,789 614
Excluding CIN2 from analysis. CIN: cervical intraepithelial neoplasia; CI: Confidence interval; DOR: diagnostic odds ratio; AUC: area under the curve; TP: true positive; FP: false positive; FN: false negative; TN: true negative.
Included studies CIN1- vs. CIN2+: Aptima [
8 –
35 ]; NucliSens EasyQ HPV [
36 –
46 ]; OncoTect [
41 ,
47 –
51 ]; PreTect HPV Proofer [
14 ,
23 ,
25 ,
31 ,
52 –
61 ]; Quantivirus [
45 ,
62 –
65 ].
CIN1- vs. CIN3+: Aptima [
8 –
15 ,
18 –
22 ,
24 ,
26 –
31 ,
33 –
35 ]; NucliSens EasyQ HPV [
36 ,
37 ,
41 ,
46 ]; OncoTect [
41 ,
47 –
50 ]; PreTect HPV Proofer [
14 ,
31 ,
59 –
61 ]; Quantivirus [
62 –
64 ].
